Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe

Pharmaceutical Technology

Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.

pharminent June 29, 2026 (Last updated: June 29, 2026)

Pharmaceutical Technology

Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.

Related Stories